He said U.S. losses alone top $500 billion a year and called gene drives “the only scalable” solution. As reported by 24/7 ...

The upcoming FDA decision for Replimune’s advanced melanoma drug could be a litmus test for the agency's future regulatory ...

Companies have long lamented Europe's fragmented capital markets, single-market adoption on pricing and clinical trials, and ...

For decades, venture capitalists have relied on a tried-and-true recipe to make money in biotech. Now that approach is being ...

Iovance Biotherapeutics argues that there is a meaningful opportunity here of more than 8,000 patients diagnosed annually in ...

However, there is one key reason the stock could still deliver outstanding returns over the long run: Its pipeline could help ...

This oncology-focused biotech, advancing multiple clinical-stage therapeutics, just reported a notable insider sale in recent ...

The recent uptick in IPOs is an encouraging signal after a drought for much of 2025. Experts point to AI as a driving force ...

If Biotech manages to break out to new highs at some point this year, it would clear a significant resistance hurdle and open ...

The six companies that have priced initial public offerings so far banked a median of $287.5 million, a figure far surpassing ...

Biotech held steady in early 2026 as M&A buyouts and rotation from the Magnificent Seven lifted IBB relative strength—read ...

The news is the latest example of the biotech industry's struggles in the Bay Area.